Results 171 to 180 of about 40,241 (253)

Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future [PDF]

, 2015
Brian Godman, Michael Wilcock, Andrew Martin, Scott Bryson, Christoph Baumgärtel, Tomasz Bochenek, Winne de Bruyn, Ljiljana Sović Brkičić, Marco D’Agata, Antra Fogele, Anna Coma Fusté, Jessica Fraeyman, Jurij Fürst, Kristina Garuolienė, Harald Herholz, Mikael Hoffmann, Sisira Jayathissa, Hye-Young Kwon, Irene Langner, Marija Kalaba, Eva Karlsson, Ott Laius, Vanda Marković‐Peković, Einar Magnússon, Stuart McTaggart, Scott Metcalfe, Hanne Bak Pedersen, Jutta Piessnegger, Anne Marthe Ringerud, Gisbert Selke, Catherine Sermet, Krijn Schiffers, Peter Skiöld, Juraj Slabý, D Tomek, Anita Viksna, Agnès Vitry, Corinne Zara, Rickard E. Malmström   +38 more
openalex   +1 more source

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]

World J Gastroenterol
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.   +8 more
europepmc   +1 more source

Regional management of biosimilars in Germany [PDF]

, 2016
Mathias Flume
openalex   +1 more source

A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability. [PDF]

Front Pharmacol
Song Y, Shin G, Choi G, Han E, Ou HT, Bae S.   +5 more
europepmc   +1 more source

LB1011 Cost and access changes with TNFa inhibitor biosimilars entering the market [PDF]

J.V. Visingardi, Bob E. Sherwood
openalex   +1 more source

PSY55 Entry and Access Expectation for Biosimilars in the United States [PDF]

, 2012
Eric Schwartz, A.J. Gould
openalex   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI) [PDF]

Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
openalex   +1 more source

The economic pressures for biosimilar drug use in cancer medicine [PDF]

, 2012
Paul Cornes
openalex   +1 more source

Innovative approach to support therapeutic proteins' similarity in hydrodynamic size using high-throughput dynamic light scattering and forced degradation. [PDF]

Sci Rep
Bhirde A, Harish S, Trunfio N, de Luna IF, Smith W, Fu Q.   +5 more
europepmc   +1 more source

Biosimilars [PDF]

Pharmazie in unserer Zeit, 2012
openaire   +1 more source